For a decade, the brain was where pharmaceutical money generally went to die. Too complex, too poorly understood, too many failed trials. Nicolas Roberti, co-founding partner of the European BrainTech Fund, calls it a graveyard.
His argument is that the graveyard is about to reopen for business, and that the reason is not a single…
